NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Innovative Epilepsy Tech | NeuroPace's RNS System revolutionizes treatment for drug-resistant focal epilepsy, showcasing strong clinical efficacy and market potential |
Financial Momentum | NeuroPace reports impressive revenue growth, with 2025 projections between $93-97 million, reflecting a 16-21% year-over-year increase |
Expanding Horizons | Explore NeuroPace's strategic initiatives, including Project CARE and potential new indications, which could double its addressable market |
Market Valuation | Analyst price targets range from $15 to $20 per share, indicating significant upside potential despite current trading above Fair Value |
Metrics to compare | NPCE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNPCEPeersSector | |
---|---|---|---|---|
P/E Ratio | −11.9x | −3.8x | −0.5x | |
PEG Ratio | −0.37 | −0.28 | 0.00 | |
Price/Book | 12.1x | 2.9x | 2.6x | |
Price / LTM Sales | 3.5x | 3.7x | 3.2x | |
Upside (Analyst Target) | 99.8% | 52.1% | 45.7% | |
Fair Value Upside | Unlock | 6.2% | 8.6% | Unlock |